




# PHARMACEUTICAL 2023

Summit Therapeutics Inc.  
Rank 277 of 446





# PHARMACEUTICAL 2023

Summit Therapeutics Inc.  
Rank 277 of 446



The relative strengths and weaknesses of Summit Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Summit Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Summit Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 211% points.

The company's Economic Capital Ratio, given in the ranking table, is 23%, being 20% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	656,712
Cost of Goods Sold	0
Intangible Assets	1,798
Liabilities, Current	38,782
Liabilities, Non-Current	4,192
Other Assets	4,752
Other Compr. Net Income	304
Other Expenses	8,468
Other Liabilities	494,540
Other Net Income	-6,693
Other Revenues	15,121
Property and Equipment	906
Research and Development	51,999
Selling, General and Administrative Expense	26,743

Output Variable	Value in 1000 USD
Assets	664,168
Liabilities	537,514
Expenses	87,210
Revenues	15,121
Stockholders Equity	126,654
Net Income	-78,782
Comprehensive Net Income	-78,630
Economic Capital Ratio	23%